NEW YORK (GenomeWeb News) – Rosetta Genomics said today that it has licensed non-exclusive rights to microRNA genes for research applications from Rockefeller University.
 
The agreement covers viral and human microRNAs that Rosetta intends to add to its existing intellectual property portfolio, which currently includes two issued patents, two allowed patent applications, and 60 pending patent applications. The Rehovot, Israel-based firm previously licensed from Rockefeller rights to microRNAs for therapeutic and diagnostic uses.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.